Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

Non-alcoholic fatty liver disease is the most common form of chronic liver disease. However, effective pharmacotherapy is still lacking. Sodium-glucose cotransporter-2 inhibitors have been proven to improve non-alcoholic fatty liver disease in previous clinical trials. In this work, an updated systematic review and meta-analysis of randomized controlled trials were performed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with non-alcoholic fatty liver disease. A literature search of PubMed, Cochrane, Web of Science, Medline, and Embase was performed up to August 2024. Articles were sieved to determine eligible randomized controlled trials. Review Manager version 5.4 software was used to conduct the meta-analysis. A total of 21 randomized controlled trials with 1,311 participants were included. Compared with the controls, sodium-glucose cotransporter-2 inhibitor treatment significantly improved the controlled attenuation parameter, liver fat content, liver-to-spleen ratio, liver stiffness measurement, fibrosis-4 index, serum type IV collagen 7S level, serum alanine transaminase level, serum aspartate transaminase level, serum gamma-glutamyl transaminase level, fasting serum insulin level, homeostatic model assessment for insulin resistance, body weight, body mass index, visceral adipose tissue, and subcutaneous adipose tissue. The incidence of total adverse events was not significantly different between the sodium-glucose cotransporter-2 inhibition group and the control group. Sodium-glucose cotransporter-2 inhibitors can improve liver steatosis, liver fibrosis, liver enzymes, insulin resistance, and body composition in patients with non-alcoholic fatty liver disease. Sodium-glucose cotransporter-2 inhibitors are safe and well tolerated. Sodium-glucose cotransporter-2 inhibitors may become promising drugs for non-alcoholic fatty liver disease treatment.

Keywords

sodium-glucose co-transporter-2 inhibitors - non-alcoholic fatty liver disease - meta-analysis

Publication History

Received: 25 November 2024

Accepted after revision: 09 October 2025

Article published online:
03 November 2025

• References

• 1 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 2 Bedogni G, Palmese FFoschi FG. Nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2023; 34: 114-118
• 3 Guo X, Yin X, Liu Z. et al. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci 2022; 23: 15489
• 4 Powell EE, Wong VWSRinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-2224
• 5 Che W, Zhao M, Li X. et al. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Front Endocrinol 2022; 13: 1002916
• 6 Targher G, Tilg HByrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021; 6: 578-588
• 7 Rong L, Zou J, Ran W. et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol 2023; 13: 1087260
• 8 Tilg H, Adolph TE, Dudek M. et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021; 3: 1596-1607
• 9 Yoneda M, Kobayashi T, Iwaki M. et al. Nonalcoholic fatty liver disease as a systemic disease and the need for multidisciplinary care. Gut Liver 2023; 17: 843-852
• 10 Ranjbar G, Mikhailidis DPSahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metab Clin Exp 2019; 101: 154001
• 11 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2017; 67: 328-357
• 12 Kuchay MS, Krishan S, Mishra SK. et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 2020; 63: 2434-2445
• 13 Liu L, Yan H, Xia M. et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 2020; 36: e3292
• 14 Dai ZC, Chen JX, Zou R. et al. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol 2023; 14: 1213473
• 15 Su J, Luo Y, Hu S. et al. Advances in research on type 2 diabetes mellitus targets and therapeutic agents. Int J Mol Sci 2023; 24: 13381
• 16 Androutsakos T, Nasiri-Ansari N, Bakasis AD. et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci 2022; 23: 3107
• 17 Makri ES, Goulas APolyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021; 907: 174272
• 18 Morishita A, Tadokoro T, Fujihara S. et al. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. PLoS One 2022; 17: e0261310
• 19 Lombardi R, Mantovani A, Cespiati A. et al. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. Digestive Liver Dis 2022; 56: 551-558
• 20 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 21 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration 2021 www.training.cochrane.org/handbook
• 22 Yoneda M, Honda Y, Ogawa Y. et al. Comparing the effects of tofogliflozin and pioglitazone in non-Alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care 2021; 9: e001990
• 23 Hooshmand Gharabagh L, Shargh A, Mohammad Hosseini Azar MR. et al. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease. ClRes Hepatol Gastroenterol 2024; 48: 102279
• 24 Tobita H, Yazaki T, Kataoka M. et al. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study. J Clin Biochem Nutr 2021; 68: 173-180
• 25 Ito D, Shimizu S, Inoue K. et al. Comparison of Ipragliflozin and Pioglitazone effects on Nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017; 40: 1364-1372
• 26 Kinoshita T, Shimoda M, Nakashima K. et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Invest 2020; 11: 1612-1622
• 27 Takeshita Y, Honda M, Harada K. et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care 2022; 45: 2064-2075
• 28 Hu CL, Wang YC, Xi Y. et al. Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Indian J Pharm Sci 2020; 82: 122-129
• 29 Shi M, Zhang H, Wang W. et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complications 2023; 37: 108610
• 30 Kuchay MS, Krishan S, Mishra SK. et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial). Diabetes Care 2018; 41: 1801-1808
• 31 Taheri H, Malek M, Ismail-Beigi F. et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther 2020; 37: 4697-4708
• 32 Eriksson JW, Lundkvist P, Jansson PA. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018; 61: 1923-1934
• 33 Phrueksotsai S, Pinyopornpanish K, Euathrongchit J. et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (Aust) 2021; 36: 2952-2959
• 34 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F. et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther 2021; 12: 843-861
• 35 Hiruma S, Shigiyama FKumashiro N. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study. Diabetes, Obes Metab 2023; 25: 1576-1588
• 36 Shimizu M, Suzuki K, Kato K. et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019; 21: 285-292
• 37 Elhini SH, Wahsh EA, Elberry AA. et al. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals 2022; 15: 1516
• 38 Han E, Lee YH, Lee BW. et al. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial. J Clin Med 2020; 9: 259
• 39 Takahashi H, Kessoku T, Kawanaka M. et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun 2022; 6: 120-132
• 40 Harrison SA, Manghi FP, Smith WB. et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med 2022; 28: 1432-1438
• 41 Shibuya T, Fushimi N, Kawai M. et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes Metab 2018; 20: 438-442
• 42 Hussain M, Babar MZM, Tariq S. et al. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. Int J Diabetes Dev Ctries 2022; 42: 290-296
• 43 Dalton JE, Bolen SDMascha EJ. Publication bias: the elephant in the review. Anesth Analg 2016; 123: 812-813
• 44 Pedroza-Diaz J, Arroyave-Ospina JC, Serna Salas S. et al. Modulation of oxidative stress-induced senescence during non-alcoholic fatty liver disease. Antioxid (Basel) 2022; 11: 975
• 45 Lian CY, Zhai ZZ, Li ZF. et al. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chem Biol Interact 2020; 330: 109199
• 46 Xu R, Lian D, Xie Y. et al. SGLT-2 inhibitors for non-alcoholic fatty liver disease: a review. Front Biosci (Landmark Ed) 2023; 28: 134
• 47 Luo J, Sun P, Wang Y. et al. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. Eur J Pharmacology 2021; 907: 174304
• 48 Nogami A, Yoneda M, Iwaki M. et al. Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future. Clin Mol Hepatol 2023; 29: S123-S135
• 49 Xu X, Poulsen KL, Wu L. et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022; 7: 287
• 50 Hu J, Teng J, Hui S. et al. SGLT-2 inhibitors as novel treatments of multiple organ fibrosis. Heliyon 2024; 10: e29486
• 51 Elseweidy MM, Ali AEM, Hassanin SM. et al. Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level. Naunyn Schmiedebergs Arch Pharmacol 2024; 397: 3449-3459
• 52 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA. et al. Clinical assessment and management of liver fibrosis in nonalcoholic fatty liver disease. World J Gastroenterol 2020; 26: 5919-5943
• 53 Ishiba H, Sumida Y, Seko Y. et al. Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes. Hepatol Commun 2021; 5: 559-572
• 54 McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J 2016; 15: 817-828
• 55 Vilar-Gomez EChalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018; 68: 305-315
• 56 Ma Q, Liao X, Shao C. et al. Normalization of gamma-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterol 2021; 21: 215
• 57 Seino H. Efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial. Diabetes Ther 2021; 12: 863-877
• 58 Miyake T, Yoshida S, Furukawa S. et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Pol) 2018; 13: 402-409
• 59 Tanase DM, Gosav EM, Costea CF. et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 2020; 2020: 3920196
• 60 Lee SH, Park SYChoi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 2022; 46: 15-37
• 61 Lee KC, Wu PSLin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clinical and Molecular. Hepatology 2023; 29: 77-98
• 62 Khan RS, Bril F, Cusi K. et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019; 70: 711-724
• 63 Radlinger B, Ress C, Folie S. et al. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia 2023; 66: 754-767
• 64 Tahapary DL, Pratisthita LB, Fitri NA. et al. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr 2022; 16: 102581
• 65 Ogawa W, Araki E, Ishigaki Y. et al. New classification and diagnostic criteria for insulin resistance syndrome. Endocr J 2022; 69: 107-113
• 66 Chaney A. Obesity and nonalcoholic fatty liver disease. Nurs Clin North Am 2021; 56: 543-552
• 67 Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 2022; 12: 824
• 68 Cordeiro A, Costa R, Andrade N. et al. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?. Clin Res Hepatol Gastroenterol 2020; 44: 394-402
• 69 Pereira MJEriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019; 79: 219-230
• 70 Cusi K, Orsak B, Bril F. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165: 305-315
• 71 Zhao Y, Zhao W, Wang H. et al. Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. Med (Baltim) 2022; 101: e31508
• 72 Zhou ST, Cui W, Kong L. et al. Efficacy of sitagliptin on nonalcoholic fatty liver disease in high-fat-diet-fed diabetic mice. Curr Med Sci 2022; 42: 513-519
• 73 Ohki T, Isogawa A, Iwamoto M. et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal 2012; 2012: 496453